COX-2 expression and effects of COX-2 inhibition in colorectal carcinomas and their liver metastases

Anticancer Research

Volumn 30, Issue 6, 2010, Pages 2017-2023

  Kasper, Hans Udo ^a,b   Konze, Elisabeth ^b   Dienes, Hans Peter ^b   Stippel, Dirk Ludger ^b   Schirmacher, Peter ^b,c   Kern, Michael ^b,c  

^a Medical Center   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Colon cancer; COX 2; Liver metastases; Precision cut tissue slices

Indexed keywords

CYCLOOXYGENASE 2; MELOXICAM;

ADULT; AGED; APOPTOSIS; ARTICLE; CECUM; COLON CARCINOGENESIS; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOPLASM; DRUG EFFECT; ENZYME INHIBITION; EX VIVO STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECTUM; TUMOR BIOPSY;

ADENOMA; ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; THIAZINES; THIAZOLES; TISSUE ARRAY ANALYSIS;

EID: 77955075305     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Kasper HU, Drebber U, Dries V and Dienes HP: Liver metastases: incidence and histogenesis. Z Gastroenterol 43: 1149-1157, 2005.
2. August DA, Sugarbaker PH, Ottow RT, Gianola FJ and Schneider PD: Hepatic resection of colorectal metastases. Influence of clinical factors and adjuvant intraperitoneal 5-fluorouracil via Tenckhoff catheter on survival. Ann Surg 201: 210-218, 1985.
3. Labianca R, Beretta G, Gatta G, de Braud F and Wils J: Colon cancer. Crit Rev Oncol Hematol 51: 145-170, 2004.
4. Rodgers MS and McCall JL: Surgery for colorectal liver metastases with hepatic lymph node involvement: a systematic review. Br J Surg 87: 1142-1155, 2000.
5. Kato T, Yasui K, Hirai T, Kanemitsu Y, Mori T, Sugihara K, Mochizuki H and Yamamoto J: Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy: analysis of prognostic factors for 763 cases recorded at 18 institutions. Dis Colon Rectum 46: S22-31, 2003.
6. Smith WL, Garavito RM and DeWitt DL: Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 271: 33157-33160, 1996.
7. Subbaramaiah K and Dannenberg AJ: Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 24: 96-102, 2003.
8. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB and Lipsky PE: Cyclooxygenase in biology and disease. FASEB J 12: 1063-1073, 1998.
9. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK and Levin B: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342: 1946-1952, 2000.
10. Tachimori A, Yamada N, Amano R, Ohira M and Hirakawa K: Combination therapy of S-1 with selective cyclooxygenase-2 inhibitor for liver metastasis of colorectal carcinoma. Anticancer Res 28: 629-638, 2008.
11. Chen WS, Wei SJ, Liu JM, Hsiao M, Kou-Lin J and Yang WK: Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac. Int J Cancer 91: 894-899, 2001.
12. Kakiuchi Y, Tsuji S, Tsujii M, Murata H, Kawai N, Yasumaru M, Kimura A, Komori M, Irie T, Miyoshi E, Sasaki Y, Hayashi N, Kawano S and Hori M: Cyclooxygenase-2 activity altered the cell-surface carbohydrate antigens on colon cancer cells and enhanced liver metastasis. Cancer Res 62: 1567-1572, 2002.
13. de Heer P, Sandel MH, Guertens G, de Boeck G, Koudijs MM, Nagelkerke JF, Junggeburt JM, de Bruijn EA, van de Velde CJ and Kuppen PJ: Celecoxib inhibits growth of tumors in a syngeneic rat liver metastases model for colorectal cancer. Cancer Chemother Pharmacol 62: 811-819, 2008.
14. Ochiai H, Nakanishi Y, Fukasawa Y, Sato Y, Yoshimura K, Moriya Y, Kanai Y, Watanabe M, Hasegawa H, Kitagawa Y, Kitajima M and Hirohashi S: A new formula for predicting liver metastasis in patients with colorectal cancer: immunohistochemical analysis of a large series of 439 surgically resected cases. Oncology 75: 32-41, 2008.
15. Thun MJ, Henley SJ and Patrono C: Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94: 252-266, 2002.
16. Chan AT, Ogino S and Fuchs CS: Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 356: 2131-2142, 2007.
17. Iwama T: NSAIDs and colorectal cancer prevention. J Gastroenterol 44(Suppl 19): 72-76, 2009.
18. Waskewich C, Blumenthal RD, Li H, Stein R, Goldenberg DM and Burton J: Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res 62: 2029-2033, 2002.
19. Reddy BS, Hirose Y, Lubet R, Steele V, Kelloff G, Paulson S, Seibert K and Rao CV: Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 60: 293-297, 2000.
20. Phillips RK, Wallace MH, Lynch PM, Hawk E, Gordon GB, Saunders BP, Wakabayashi N, Shen Y, Zimmerman S, Godio L, Rodrigues-Bigas M, Su LK, Sherman J, Kelloff G, Levin B and Steinbach G: A randomised, double-blind, placebo-controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 50: 857-860, 2002.
21. Parrish AR, Gandolfi AJ and Brendel K: Precision-cut tissue slices: applications in pharmacology and toxicology. Life Sci 57: 1887-1901, 1995.
22. Kasper HU, Dries V, Drebber U, Kern MA, Dienes HP and Schirmacher P: Precision-cut tissue slices of the liver as morphological tool for investigation of apoptosis. In Vivo 19: 423-431, 2005.
23. Remmele W and Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8: 138-140, 1987.
24. Bamba H, Ota S, Kato A, Adachi A, Itoyama S and Matsuzaki F: High expression of cyclooxygenase-2 in macrophages of human colonic adenoma. Int J Cancer 83: 470-475, 1999.
25. Khan KN, Masferrer JL, Woerner BM, Soslow R and Koki AT: Enhanced cyclooxygenase-2 expression in sporadic and familial adenomatous polyposis of the human colon. Scand J Gastroenterol 36: 865-869, 2001.
26. Sinicrope FA and Gill S: Role of cyclooxygenase-2 in colorectal cancer. Cancer Metastasis Rev 23: 63-75, 2004.
27. Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J and Koki AT: COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 89: 2637-2645, 2000.
28. Yu JR, Wu YJ, Qin Q, Lu KZ, Yan S, Liu XS and Zheng XS: Expression of cyclooxygenase-2 in gastric cancer and its relation to liver metastasis and long-term prognosis. World J Gastroenterol 11: 4908-4911, 2005.
29. Hull MA, Fenwick SW, Chappie KS, Scott N, Toogood GJ and Lodge JP: Cyclooxygenase-2 expression in colorectal cancer liver metastases. Clin Exp Metastasis 18: 21-27, 2000.
30. Kobayashi H, Sugihara K, Uetake H, Higuchi, Yasuno M, Enomoto M, Iida S, Lenz HJ, Danenberg KD and Danenberg PV: Messenger RNA expression of COX-2 and angiogenic factors in primary colorectal cancer and corresponding liver metastasis. Int J Oncol 34: 1147-53, 2009.
31. Nakamoto RH, Uetake H, Iida S, Kolev YV, Soumaoro LT, Takagi Y, Yasuno M and Sugihara K: Correlations between cyclooxygenase-2 expression and angiogenic factors in primary tumors and liver metastases in colorectal cancer. Jpn J Clin Oncol 37: 679-685, 2007.
32. Agui T, McConkey DJ and Tanigawa N: Comparative study of various biological parameters, including expression of survivin, between primary and metastatic human colonic adenocarcinomas. Anticancer Res 22: 1769-1776, 2002.
33. Prall F, Gringmuth U, Nizze H and Barten M: Microvessel densities and microvascular architecture in colorectal carcinomas and their liver metastases: significant correlation of high microvessel densities with better survival. Histopathology 42: 482-491, 2003.
34. Sun Y, Tang XM, Half E, Kuo MT and Sinicrope FA: Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells. Cancer Res 62: 6323-6328, 2002.
35. Tang X, Sun YJ, Half E, Kuo MT and Sinicrope F: Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells. Cancer Res 62: 4903-4908, 2002.
36. Labayle D, Fischer D, Vielh P, Drouhin F, Pariente A, Bories C, Duhamel O, Trousset M and Attali P: Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 101: 635-639, 1991.
37. Sawaoka H, Kawano S, Tsuji S, Tsujii M, Gunawan ES, Takei Y, Nagano K and Hori M: Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am J Physiol 274: G1061-1067, 1998.
38. Liu XH, Yao S, Kirschenbaum A and Levine AC: NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res 58: 4245-4249, 1998.
39. Li S, Tong Q, Zhang W, Wang Q, Chen Z and Wu Q: Mechanism of growth inhibitory effects of cyclooxygenase-2 inhibitor-NS398 on cancer cells. Cancer Invest 26: 333-337, 2008.
40. Fenwick SW, Toogood GJ, Lodge JP and Hull MA: The effect of the selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastases. Gastroenterology 125: 716-729, 2003.
41. Gately S and Li WW: Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin Oncol 31: 2-11, 2004.
42. Yamauchi T, Watanabe M, Hasegawa H, Nishibori H, Ishii Y, Tatematsu H, Yamamoto K, Kubota T and Kitajima M: The potential for a selective cyclooxygenase-2 inhibitor in the prevention of liver metastasis in human colorectal cancer. Anticancer Res 23: 245-249, 2003.
43. Ishizaki T, Katsumata K, Tsuchida A, Wada T, Mori Y, Hisada M, Kawakita H and Aoki T: Etodolac, a selective cyclooxygenase-2 inhibitor, inhibits liver metastasis of colorectal cancer cells via the suppression of MMP-9 activity. Int J Mol Med 17: 357-362, 2006.